All In Biotech

Drug Trial Radar · NCT05445843

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

95

Actual

Start

Dec 6, 2022

Primary completion

Nov 4, 2024

Study completion Oct 28, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the antitumor activity and safety of JDQ443 single-agent as first-line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS G12C mutation and have a PD-L1 expression \< 1% (cohort A) or a PD-L1 expression ≥ 1% and an STK11 co-mutation (cohort B).

Conditions

  • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Interventions

  • JDQ443Drug

    JDQ443 per os (PO) 200 mg twice a day continuously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) as Determined by the Investigator in Cohort ATime frame: Up to approximately 22 months

Locations

45 sites in 19 countries. Site status is shown where the registry gives one.

  • The Brown University Oncology Group

    Providence, Rhode Island

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Pilar, Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina

  • Novartis Investigative Site

    Feldkirch, Austria

  • Novartis Investigative Site

    Wels, Austria

  • Novartis Investigative Site

    Sint-Niklaas, Oost Vlaanderen, Belgium

  • Novartis Investigative Site

    Roeselare, West-Vlaanderen, Belgium

  • Novartis Investigative Site

    Belo Horizonte, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Changsha, Hunan, China

  • Novartis Investigative Site

    Bron, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Saint-Herblain, France

  • Novartis Investigative Site

    Strasbourg, France

  • Novartis Investigative Site

    Marseille, Bouches Du Rhone, France

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Oldenburg, Germany

  • Novartis Investigative Site

    Tübingen, Germany

  • Novartis Investigative Site

    Kempten (Allgäu), Bavaria, Germany

  • Novartis Investigative Site

    Halle, Saxony-Anhalt, Germany

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Mátraháza, Hungary

  • Novartis Investigative Site

    Thellakom Kottayam, Kerala, India

  • Novartis Investigative Site

    Varanasi, Uttar Pradesh, India

  • Novartis Investigative Site

    Bari, BA, Italy

  • Novartis Investigative Site

    Rozzano, MI, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Orbassano, TO, Italy

  • Novartis Investigative Site

    George Town, Pulau Pinang, Malaysia

  • Novartis Investigative Site

    Kuching, Sarawak, Malaysia

  • Novartis Investigative Site

    Breda, North Brabant, Netherlands

  • Novartis Investigative Site

    Leeuwarden, Provincie Friesland, Netherlands

  • Novartis Investigative Site

    Porto, Portugal

  • Novartis Investigative Site

    Barcelona, Spain

  • Novartis Investigative Site

    Madrid, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.